Palvella Therapeutics (NASDAQ:PVLA) Stock Price Down 5.9% – Here’s What Happened

by · The Cerbat Gem

Palvella Therapeutics, Inc. (NASDAQ:PVLA – Get Free Report)’s share price traded down 5.9% during trading on Tuesday . The company traded as low as $101.76 and last traded at $102.64. 72,891 shares changed hands during mid-day trading, a decline of 47% from the average session volume of 138,706 shares. The stock had previously closed at $109.07.

Analyst Upgrades and Downgrades

Several equities research analysts recently commented on the stock. Oppenheimer reissued an “outperform” rating and issued a $200.00 price target on shares of Palvella Therapeutics in a report on Monday, December 15th. TD Cowen raised their price target on shares of Palvella Therapeutics from $97.00 to $133.00 and gave the company a “buy” rating in a research note on Tuesday, December 16th. Raymond James Financial reiterated a “strong-buy” rating and set a $193.00 price objective on shares of Palvella Therapeutics in a research note on Tuesday, December 16th. UBS Group restated a “buy” rating and issued a $143.00 target price on shares of Palvella Therapeutics in a research report on Monday, December 15th. Finally, Stifel Nicolaus boosted their price target on Palvella Therapeutics from $87.00 to $145.00 and gave the stock a “buy” rating in a research report on Monday, November 24th. Two analysts have rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Palvella Therapeutics currently has a consensus rating of “Buy” and an average price target of $155.60.

View Our Latest Research Report on Palvella Therapeutics

Palvella Therapeutics Price Performance

The company has a market cap of $1.20 billion, a price-to-earnings ratio of -38.52 and a beta of -0.20. The firm has a 50 day simple moving average of $86.46 and a 200-day simple moving average of $58.24.

Palvella Therapeutics (NASDAQ:PVLA – Get Free Report) last posted its quarterly earnings data on Monday, November 10th. The company reported ($1.03) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.85) by ($0.18). Research analysts anticipate that Palvella Therapeutics, Inc. will post -3.69 EPS for the current fiscal year.

Insider Buying and Selling

In other Palvella Therapeutics news, COO Kathleen Goin sold 4,302 shares of Palvella Therapeutics stock in a transaction dated Wednesday, December 17th. The stock was sold at an average price of $96.47, for a total value of $415,013.94. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 20.50% of the stock is owned by company insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in PVLA. Clio Asset Management LLC purchased a new position in shares of Palvella Therapeutics in the 2nd quarter valued at about $2,063,000. Frazier Life Sciences Management L.P. increased its stake in shares of Palvella Therapeutics by 4.7% during the second quarter. Frazier Life Sciences Management L.P. now owns 722,400 shares of the company’s stock worth $16,283,000 after buying an additional 32,388 shares during the period. XTX Topco Ltd acquired a new stake in Palvella Therapeutics in the second quarter valued at approximately $399,000. Woodline Partners LP purchased a new position in Palvella Therapeutics in the first quarter worth approximately $5,435,000. Finally, Goldman Sachs Group Inc. acquired a new position in Palvella Therapeutics during the 1st quarter worth approximately $533,000. Hedge funds and other institutional investors own 40.11% of the company’s stock.

Palvella Therapeutics Company Profile

(Get Free Report)

Palvella Therapeutics, Inc (NASDAQ: PVLA) is a clinical‐stage biopharmaceutical company devoted to the discovery and development of innovative therapies for immunological and inflammatory diseases. The company employs a proprietary small‐molecule and biologics platform to identify and modulate key molecular pathways that drive neutrophil‐ and complement‐mediated inflammation, aiming to deliver targeted treatment options for patients with significant unmet medical needs.

Palvella’s pipeline comprises several preclinical assets designed to address both prevalent chronic inflammatory conditions and rare autoinflammatory syndromes.

Further Reading